Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 12/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 3/20 | 0.51 |
| ▸ | RXRB | P28702 | 3/20 | 0.51 |
| ▸ | RXRG | P48443 | 3/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716953 | 1.00 | POLQ (0.61) | POLQCES2RXRARXRBRXRG | |
| SCHEMBL6193603 | 0.87 | POLQ (0.58) | POLQCES2RXRARXRBRXRG | |
| SCHEMBL8717273 | 0.87 | RXRA (0.59) | POLQRXRARXRBRXRG | |
| SCHEMBL5574328 | 0.86 | CES2 (0.53) | POLQCES2RXRARXRBRXRG | |
| SCHEMBL31589470 | 0.84 | POLQ (0.56) | POLQCES2 | |
| SCHEMBL14562998 | 0.84 | POLQ (0.56) | POLQCES2 | |
| SCHEMBL14263469 | 0.84 | POLQ (0.59) | POLQCES2PTGDR2 | |
| SCHEMBL3135089 | 0.84 | RXRA (0.53) | POLQCES2RXRARXRBRXRG | |
| SCHEMBL15094094 | 0.83 | POLQ (0.51) | POLQCES2PTGDR2 | |
| SCHEMBL512428 | 0.82 | IDO1 (0.51) | POLQRXRARXRBRXRGPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107381-A1 | DNA POLYMERASE THETA INHIBITORS, COMPOSITIONS THEREOF, COMPOSITIONS FURTHER COMPRISING A DNA DEPENDENT PROTEIN KINASE, AND USES OF BOTH IN GENE EDITING FIELD | JUNO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4731219-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | Promega Corporation (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025110780-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-30 | — | — | WO | disclosed |
| US-20250003974-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | PROMEGA CORPORATION | 2025-01-02 | — | — | US | disclosed |
| WO-2024263837-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | PROMEGA CORPORATION (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0776203-A4 | N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO INC (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0776208-A4 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO INC (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997048686-A1 | NOVEL N-1 ALKYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPIN-3-YL)-3-AMIDES | MERCK & CO., INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5658901-A | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines | MERCK & CO., INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0776208-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO. INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| EP-0776203-A1 | N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO. INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5633251-A | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996005827-A1 | N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO., INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1996005839-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO., INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250003974-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | POLQ, POLB, POLM | POLQ 1/4885CES2 502/4885RXRA 2244/4885 |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | POLQ 4283/4885CES2 3524/4885RXRA 4631/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | POLQ 4269/4885CES2 2130/4885RXRA 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.